R&D at other companies
Other financials
Where this comes from
Reported directly by ARS Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: ARS Pharmaceuticals, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →
Ask your AI about ARS Pharmaceuticals, Inc.'s r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ARS Pharmaceuticals, Inc.'s R&D?
- ARS Pharmaceuticals, Inc. (SPRY) reported R&D of $4.34M in Q1 2026.
- How has ARS Pharmaceuticals, Inc.'s R&D changed year-over-year?
- ARS Pharmaceuticals, Inc.'s R&D increased by 46.9% year-over-year, from $2.95M to $4.34M.
- What is the long-term trend for ARS Pharmaceuticals, Inc.'s R&D?
- Over 3 years (2022 to 2025), ARS Pharmaceuticals, Inc.'s R&D has grown at a -10.5% compound annual growth rate (CAGR), from $18.38M to $13.18M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.